Suppr超能文献

使用Thoraflex Hybrid装置进行全主动脉弓置换术:从美国的研究性使用到联邦批准使用的演变

Total aortic arch replacement using the Thoraflex Hybrid device: evolution from investigational to federally approved use in the United States.

作者信息

Orozco-Sevilla Vicente, Coselli Joseph S, Green Susan Y, Glover Veronica A, Garnica Ricardo de Jesus Avendaño, Xue Anna H, Barron Lauren K, Moon Marc R

机构信息

Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.

Department of Cardiovascular Surgery, The Texas Heart Institute, Houston, TX, USA.

出版信息

Ann Cardiothorac Surg. 2025 Jul 31;14(4):279-290. doi: 10.21037/acs-2025-evet-0070. Epub 2025 Jul 29.

Abstract

BACKGROUND

After the US Food and Drug Administration (FDA) approved the Thoraflex Hybrid device in April 2022, hybrid devices to facilitate total arch replacement (TAR) became commercially available in the United States. However, little is known about how the Thoraflex device has been used since then. We present our experience (2016-2025) with this device.

METHODS

At our practice, 62 patients [median age, 65 (54-73) years] underwent frozen elephant trunk (FET) TAR with the Thoraflex device: 14 under an investigational device exemption (IDE) (2016-2018) and 48 after FDA approval (2022-2025). Both Ante-Flo (straight) and Plexus (branched) models were used.

RESULTS

Patients with aortic dissection were common (n=38; 61%). Many patients had prior open or endovascular aortic repair (n=28; 45%). Initial cannulation was commonly done via the innominate artery (n=30; 48%) or the right axillary artery (n=22; 36%). Both branched and island strategies were used to reattach the brachiocephalic arteries. Selectively, left subclavian artery (LSCA) bypass was performed before TAR in 18 patients (29%). The distal anastomosis was performed proximal to the LSCA in 27 repairs (43%). A short (10-cm) endograft extension was used in most cases (n=49; 79%). Eight (13%) patients underwent concomitant aortic root replacement. Overall, four patients (7%) had operative deaths, and three (5%) were discharged with stroke or persistent need for renal dialysis. Two patients had spinal cord deficits that resolved before discharge. Twenty-five downstream extensions (12 open, 13 endovascular) were needed in 22 patients; two patients underwent more than one repair. After discharge, seven additional patients died within one year of surgery.

CONCLUSIONS

TAR is a complex procedure. Patients requiring such repair tend to have substantial disease that often eventually necessitates subsequent downstream aortic repair, especially when dissection is present. Using the Thoraflex Hybrid device in TAR results in good early outcomes and provides a reliable base for extension.

摘要

背景

2022年4月美国食品药品监督管理局(FDA)批准Thoraflex Hybrid装置后,用于全弓置换(TAR)的杂交装置在美国开始商业化供应。然而,自那时以来Thoraflex装置的使用情况鲜为人知。我们介绍了我们使用该装置的经验(2016 - 2025年)。

方法

在我们的医疗实践中,62例患者[中位年龄65(54 - 73)岁]接受了使用Thoraflex装置的象鼻支架冷冻术(FET)TAR:14例在研究性器械豁免(IDE)下进行(2016 - 2018年),48例在FDA批准后进行(2022 - 2025年)。使用了Ante - Flo(直管型)和Plexus(分支型)两种型号。

结果

主动脉夹层患者很常见(n = 38;61%)。许多患者曾接受过开放性或血管腔内主动脉修复术(n = 28;45%)。初始插管通常通过无名动脉(n = 30;48%)或右腋动脉(n = 22;36%)进行。采用分支和岛状策略重新连接头臂动脉。选择性地,18例患者(29%)在TAR前进行了左锁骨下动脉(LSCA)旁路移植术。27例修复手术(43%)的远端吻合在LSCA近端进行。大多数情况下使用了短(10厘米)的血管内移植物延伸段(n = 49;79%)。8例(13%)患者同时进行了主动脉根部置换。总体而言,4例患者(7%)手术死亡,3例(5%)出院时伴有中风或持续需要肾透析。2例患者出现脊髓功能缺损,出院前恢复。22例患者需要进行25次下游延伸手术(12次开放手术,13次血管腔内手术);2例患者接受了不止一次修复手术。出院后,又有7例患者在术后一年内死亡。

结论

TAR是一个复杂的手术。需要这种修复的患者往往患有严重疾病,最终通常需要进行后续的下游主动脉修复,尤其是在存在夹层的情况下。在TAR中使用Thoraflex Hybrid装置可获得良好的早期效果,并为延伸提供可靠基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dee/12343152/dcae608893cd/acs-14-04-279-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验